Loading ...
inserting a protease resistant methylene - oxy ( -CH2-O- ) pseudoamide function at the cleavage site of 251Asp(passive) were designed byPeptide analogs
increasing their resistance to digestive enzymesthus creatinganalog peptides
Therefore , one strategy to circumvent this poor immunogenicity isto designsynthetic immunogenic analog peptides
We also used RRMto designthe peptide analogue
K4W , the following five steps take place : A ) the residue of interest ( lys4 ) and the two surrounding amino acids ( asp3 and cys5 ) are copied into a new pdb file ; B ) the side chain atoms of the excised tripeptide are stripped from the analog pdb file , the backbone atoms and the beta carbon atom are retained ; C ) the amino acid at the point of mutation is replacedto createthe peptide analog ( lys4→trp4
to improve the intracellular uptake and the antitumor activity of epirubicin ( EPR(passive) was designedpeptide amphiphile
professors at the University of Arizona to diagnose and treat psychogenic erectile dysfunction in impotent men(passive) designed bya peptide hormone analog
The in vitro analysis of antimicrobial activity in NHS with cefepimeresultedin a peptide ( analog G
Although Exendin-4 extended stay in the body from the original hours to several tens of hours , or even longer , but the N - terminal His - Gly dipeptide is still being within the enzyme ( e.g. DPP IV ) cut possibilitiesleadingto the glucagon analog peptide
to target tumors with radiolabeled molecules that bind to specific receptors expressed by the tumordesignedto target tumors with radiolabeled molecules that bind to specific receptors expressed by the tumor
α - thrombin from cleaving the peptide NATLDPRSFLLR ( SEQ ID NO:3 ) between arginine and serine , the identical place on PAR1 that thrombin cleaves to activate this receptorpreventedα - thrombin from cleaving the peptide NATLDPRSFLLR ( SEQ ID NO:3 ) between arginine and serine , the identical place on PAR1 that thrombin cleaves to activate this receptor
with one of Zealand Pharma ’s peptide modification technologiespartially inventedwith one of Zealand Pharma ’s peptide modification technologies
the development of CIA in the animal modelpreventthe development of CIA in the animal model
the inhibition(passive) caused bythe inhibition
the contact ofthe subunits at this sitepreventingthe contact ofthe subunits at this site
and fully owned by Zealand and observed to have a favorable physical and chemical stability in liquid solutioninventedand fully owned by Zealand and observed to have a favorable physical and chemical stability in liquid solution
to our initial experienceledto our initial experience